

Anti-EGFR Antibody-HRP (6P389)

Product Details

| | |
|---------------|------------|
| Ig Type: | Rabbit IgG |
| Reactivity: | Human |
| Conjugation: | HRP |
| Clone: | 6P389 |
| Purification: | Protein A |

Applications

| | |
|--------------|--------------------|
| Application: | ELISA |
| Recommended | ELISA: 0.1-1 µg/ml |

Properties

| | |
|----------------------|--|
| Stability & Storage: | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. Keep away from direct sunlight. |
| Shipping: | Shipping with blue ice. |

Antigen Details

| | |
|------------------|--|
| Immunogen: | Recombinant Protein: Human EGFR Protein (Catalog#10001-H08H) |
| Antigen Species: | Human |
| Synonyms: | HER1;mENA;epidermal growth factor receptor;ERBB1;ERBB;PIG61;NISBD2 |
| Biology Area: | Cancer Drug Targets, Receptor Tyrosine Kinases (RTKs) |

Research Background

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF- α , betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481